Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > CRDF Cardiff Oncology > Detailed Quotes

CRDF Cardiff Oncology

Watchlist
1.740
+0.010+0.58%
Close  01/27 16:00 ET
1.7400.0000.00%
Post Mkt Price 01/27 16:22 ET
High
1.786
Open
1.730
Turnover
215.23K
Low
1.720
Pre Close
1.730
Volume
122.82K
Market Cap
77.74M
P/E(TTM)
Loss
52wk High
3.778
Shares
44.68M
P/E(Static)
Loss
52wk Low
1.130
Float Cap
69.99M
Bid/Ask %
-95.12%
Historical High
81.480
Shs Float
40.22M
Volume Ratio
0.75
Historical Low
0.450
Dividend TTM
--
Div Yield TTM
--
P/B
0.69
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.31%
Amplitude
3.82%
Avg Price
1.752
Lot Size
1
Float Cap
69.99M
Bid/Ask %
-95.12%
Historical High
81.480
Shs Float
40.22M
Volume Ratio
0.75
Historical Low
0.450
Dividend TTM
--
P/B
0.69
Dividend LFY
--
Turnover Ratio
0.31%
Amplitude
3.82%
Avg Price
1.752
Lot Size
1
Price Forecast

News

Comment

No Data

Company Overview More
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
CEO: Dr. Mark Erlander, PhD
Market: NASDAQ
Listing Date: 07/31/2003
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist